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Analgesia and unwanted benzodiazepine effects
in point-mutated mice expressing only one
benzodiazepine-sensitive GABAA receptor subtype
William T. Ralvenius1,2, Dietmar Benke1,2, Mario A. Acun˜a1,2, Uwe Rudolph3,4 & Hanns Ulrich Zeilhofer1,2,5
Agonists at the benzodiazepine-binding site of GABAA receptors (BDZs) enhance synaptic
inhibition through four subtypes (a1, a2, a3 and a5) of GABAA receptors (GABAAR). When
applied to the spinal cord, they alleviate pathological pain; however, insufﬁcient efﬁcacy after
systemic administration and undesired effects preclude their use in routine pain therapy.
Previous work suggested that subtype-selective drugs might allow separating desired
antihyperalgesia from unwanted effects, but the lack of selective agents has hitherto
prevented systematic analyses. Here we use four lines of triple GABAAR point-mutated mice,
which express only one benzodiazepine-sensitive GABAAR subtype at a time, to show that
targeting only a2GABAARs achieves strong antihyperalgesia and reduced side effects (that is,
no sedation, motor impairment and tolerance development). Additional pharmacokinetic and
pharmacodynamic analyses in these mice explain why clinically relevant antihyperalgesia
cannot be achieved with nonselective BDZs. These ﬁndings should foster the development of
innovative subtype-selective BDZs for novel indications such as chronic pain.
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C
hronic pain is a severe medical condition affecting
hundreds of millions of patients worldwide. It is widely
accepted that diminished inhibition in pain-processing
circuits of the spinal dorsal horn is a major contributor to
different chronic pain forms1–4. We have previously
demonstrated that local spinal application of BDZ site ligands
that positively modulate GABAAR function alleviates neuropathic
and inﬂammatory pain in rodents5. Translation of these results to
routine systemic pain treatment, however, requires a separation of
desired antihyperalgesia from unwanted side effects. This
separation appears potentially feasible based on the existence of
different GABAAR subtypes.
Most GABAARs in the brain and spinal cord are heteropenta-
meric ion channels composed of two a, two b and one g2 subunit6.
The high-afﬁnity binding site for BDZs is formed by an interface
between one a subunit and the g2 subunit. High-afﬁnity binding of
BDZs at this site requires the presence of a histidine residue at a
conserved site in the N-terminal domain of the a subunit. This
conserved histidine is present in a1, a2, a3 or a5 subunits, but not
in the a4 and a6 subunits7. Mutation of the histidine residue into
an arginine dramatically reduces the afﬁnity of GABAARs to BDZs
without changing their responses to GABA8. The generation of
histidine to arginine (H-R) point-mutated mice for each of the
four BDZ-sensitive GABAAR subunits has allowed attributing the
different in vivo effects of BDZs to deﬁned GABAAR subtypes9.
Most importantly, it was shown that the sedative effects of BDZs
were strongly reduced in mice carrying the H-R point mutation
in their a1 subunits10,11, while point-mutating the a2 subunits led
to a loss in the anxiolytic effects of BDZs12. Using this approach,
we could demonstrate that mice whose a2GABAARs had
been rendered BDZ-insensitive show drastically reduced
antihyperalgesic responses to spinal diazepam (DZP)5. A general
consensus on the question, which GABAAR subtype should best be
targeted to achieve maximal antihyperalgesic responses and to best
avoid undesired effects has not been reached. A similarly open
question is why classical BDZs are largely devoid of analgesic
actions in patients.
Highly selective tool compounds that would allow addressing
these questions pharmacologically are still lacking13. For this
reason, we have generated triple GABAAR point-mutated mice, in
which only a single GABAAR subtype remains BDZ-sensitive.
We designate these mice hereafter as HRRR, short for
a1H;a2R;a3R;a5R (that is, a mouse in which only a1GABAARs
are left BDZ-sensitive) and, accordingly, as RHRR, RRHR, RRRH
for mouse lines, in which either only a2, a3 or a5 subunits
remain BDZ-sensitive. In these mice, the action of the classical
normally nonselective BDZ agonist DZP should mimic the action
of fully subtype-selective compounds. Such a genetic approach
also avoids possible confounding factors of subtype-selective
compounds such as pharmacokinetic differences and unknown
speciﬁcity proﬁles of drug metabolites. With the use of triple
GABAAR point-mutated mice, we were not only able to perform
a systematic analysis on the GABAAR subtypes best targeted for
optimal antihyperalgesia and least-pronounced side effects;
however, we also provide an explanation why classical
(nonselective) BDZs are largely devoid of clinically relevant
analgesic properties.
Results
Spinal distribution of subtype-speciﬁc BDZ-binding sites. In
the ﬁrst series of experiments, we characterized the distribution
pattern of the four subtypes of BDZ-sensitive GABAARs (‘BDZ
receptors’) in the spinal dorsal horn of triple point-mutated mice.
Using immunocytochemistry, we veriﬁed that neither the regional
distribution nor the expression levels of a1, a2, a3 and a5
subunits and of the g2 subunit differed between wild-type (wt)
mice and the four strains of triple point-mutated mice (Fig. 1a,b).
Similarly, the total number of BDZ-binding sites (wt receptors
plus H-R point-mutated receptors) quantiﬁed through
[3H]Ro15-4513 autoradiography was unchanged (Fig. 1c). Spinal
autoradiography with [3H]ﬂumazenil that binds with high afﬁnity
only to nonpoint-mutated GABAARs allowed a quantitative
analysis of each of the four subtypes of BDZ-binding sites in
isolation. In wt mice, [3H]ﬂumazenil exhibited speciﬁc binding
throughout the spinal grey matter with enrichment in the dorsal
horn and around the central canal. The density of binding sites in
the dorsal horn was highest for the a3GABAAR subtype, followed
by a2 and a1, and lowest for the a5 subtype (Fig. 1d). The a1
subtype was concentrated around the central canal, a2 was most
abundant in the superﬁcial dorsal horn, where nociceptive ﬁbres
terminate, and a3 was found throughout the dorsal horn and
around the central canal, while a5 was generally weak. The dis-
tribution of subtype-speciﬁc [3H]ﬂumazenil binding in the four
strains of GABAAR triple point-mutated mice matched the dis-
tribution of the subunits determined with immunocytochemistry
on a gross scale. However, the sum of the binding sites in the four
strains of triple point-mutated mice was about twice as high as
the total number of binding sites in wt mice. The results from the
immunocytochemistry and [3H]Ro15-4513 autoradiography lar-
gely rule out changes in protein expression as the underlying
cause. Instead, the [3H]ﬂumazenil data are consistent with a high
prevalence of GABAARs containing two different a subunits14,15
and with a model of the GABAAR assembly in which nonpoint-
mutated a subunits have a higher probability for interaction with
the g2 subunit than H-R point-mutated subunits16. This
conclusion is further supported by the only marginal reduction
of BDZ binding observed in spinal cords of the four single point-
mutated mouse lines (Fig. 1e).
Antihyperalgesia by single BDZ-sensitive GABAARs subtypes.
We next used the triple point-mutated mice to predict pharma-
cological actions of subtype-selective BDZ site agonists and
treated them with DZP, a classical nonselective BDZ, whose
agonistic activity was restricted to a single GABAAR subtype in
triple point-mutated mice. We ﬁrst focused on the anti-
hyperalgesic potential of such an approach (that is, the potential
to reduce neuropathy-induced hyperalgesia) and tested DZP in
mice subjected to the chronic constriction injury (CCI; ref. 17)
model. Baseline mechanical and heat sensitivity were statistically
indistinguishable in all strains of mice analysed and all strains of
mice developed similar hyperalgesia after CCI (Table 1). All
subsequent experiments with DZP were performed on an a1R
point-mutated background to avoid DZP-induced sedation,
which is a potential confounding factor in behavioural pain tests.
We ﬁrst tested different doses of systemic (per os (p.o.)) DZP in
a1 point-mutated RHHH mice (Fig. 2a,b). On the basis of these
results, we chose a dose of 10mg kg 1 body weight, which is
close to the ED70, for subsequent experiments. We then asked
which GABAAR subtype exerts the strongest antihyperalgesic
action and tested the effects of DZP on mechanical (von Frey
ﬁlament test) and heat (Hargreaves test) hyperalgesia in the four
strains of GABAAR triple point-mutated mice (Fig. 2c–e). For
both stimuli, the strongest effect was achieved in RHRR mice in
which only a2GABAARs were BDZ-sensitive. Exclusive targeting
of a3 and a5GABAARs (in RRHR and RRRH mice) also elicited
antihyperalgesia but to a smaller extent. Importantly, mice in
which all four BDZ receptors had been point-mutated (RRRR
mice) did not show any antihyperalgesic response. We next asked
whether targeting of a second or third GABAAR subtype in
addition to a2 would increase antihyperalgesic efﬁcacy and
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compared antihyperalgesic responses in triple point-mutated
mice with those in mice carrying only one or two point-mutated
receptors. We found only small and statistically insigniﬁcant
differences indicating that adding activity at a subtype different
from a2 did not signiﬁcantly increase antihyperalgesia (Fig. 2f).
The autoradiography data shown in Fig. 1d suggest a high
prevalence of GABAARs with two different a subunits (‘mixed
GABAARs’) in the spinal cord. Because the sum of the four
receptor subtypes detected in the triple point-mutated mice
greatly exceeded the total number of [3H]ﬂumazenil binding sites
in the wt mice, the pharmacological effect of a given GABAAR
subtype may be overestimated when tested in triple point-
mutated mice. To address this issue, we compared the level of
antihyperalgesia achieved in the triple point-mutated mice with
the loss in antihyperalgesia that occurs after mutation of the same
subunit (Fig. 2g). For both types of sensory tests (Hargreaves and
von Frey ﬁlament) and for all three a subunits under study, we
found that the level of antihyperalgesia achieved in the triple
point-mutated mice always exceeded the loss in antihyperalgesia
by mutation of the same subunit consistent with the high
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Figure 1 | Distribution of the four subtypes of BDZ-sensitive GABAARs in the spinal cord. (a,b) Immunohistochemistry. (a) Localization of GABAAR a
subunits in spinal cords of wt mice and of the four types of GABAAR triple point-mutated mice. Pseudocolour images display receptor density (lowest to
highest density, blue to yellow). Right: quantitative comparison of expression levels in wt and triple point-mutated mice. Two-way analysis of variance
(ANOVA) for interaction (a subunit  genotype): F(7,42)¼0.53, P¼0.68, n¼6 mice (three sections each) for all groups, except RRHR, where n¼ 7
mice. Panel b same as a, but for g2 subunits. ANOVA followed by Dunnett’s post hoc test. F(4,15)¼0.32; PZ0.94. n¼4 mice (three sections each) for all
genotypes. (c,d) Autoradiography. (c) [3H]Ro15-4513-binding sites indicate the distribution of all a/g GABAARs independent of their BDZ sensitivity in wt
mice and the four types of GABAAR triple point-mutated mice. H and R indicate homozygous wt and point-mutated alleles (for a1/a2/a3/a5 subunits),
respectively. Right: quantiﬁcation of [3H]Ro15-4513-binding sites in the dorsal horn. ANOVA followed by Dunnett’s post hoc test with wt as control.
F(4,10)¼ 2.89, PZ0.18, n¼ 3, for all genotypes (430 sections each). (d) Same as c, but distribution of BDZ-sensitive GABAARs labelled with
[3H]ﬂumazenil. ANOVA followed by Dunnett’s post hoc test with wt as control. F(4,55)¼40.1, ***Po0.001, n¼ 11, 12, 12, 12 and 14 mice (410 sections
each), for wt (HHHH), HRRR, RHRR, RRHR and RRRH mice, respectively. (e) Same as (d), but wt and GABAAR single point-mutated mice. F(4,42)¼0.441,
P40.66, n¼ 11, 9, 9, 9 and 9 mice, for wt(HHHH), RHHH, HRHH, HHRH and HHHR mice, respectively. All scale bars, 200 mm. All quantitative data
mean±s.e.m.
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prevalence of mixed GABAARs in the spinal cord. It is important
to note that the rank order of antihyperalgesic efﬁcacies was the
same in experiments with triple point-mutated mice and in loss-
of-function experiments in single and double point-mutated
mice, and also identical to those found in a pain model employing
chemical nociceptor activation instead of neuropathy (Fig. 2h).
Taken together, these results support a major contribution of
a2GABAARs to antihyperalgesia in different pain models.
However, because all experiments had to be conducted on an
a1 point-mutated background to avoid confounding sedation, the
relevance of a2GABAARs might be overestimated if ‘pain-
relevant’ a2GABAARs contained also a1 subunits. To address
this potential caveat we used HZ-166 (ref. 18), a novel
benzodiazepine site ligand with an improved a2/a1 selectivity
ratio19 and signiﬁcant analgesic activity already at non-sedative
doses20 (Fig. 3). Antihyperalgesia by HZ-166 was almost
completely blocked in single a2(H101R) point-mutated
(HRHH) mice, further conﬁrming that the ‘pain-relevant’
GABAARs exhibit an a2 pharmacology.
Potential undesired BDZ effects in triple point-mutated mice.
We next used the same triple point-mutated mouse approach to
investigate non-pain-related effects. In these experiments, we
focused on diminished locomotor activity (as a surrogate para-
meter of sedation), muscle strength and motor coordination. No
signiﬁcant differences were observed in the behaviour of drug-
naive wt and point-mutated mice (Table 2). The DZP treatment
strongly reduced locomotor activity in wt mice and in mice with
BDZ-sensitive GABAARs of only the a1 subtype (HRRR mice;
Fig. 4a). No sedative effects were observed in any of the other
triple point-mutated mice. Mice with only a2 BDZ-sensitive
GABAARs (RHRR mice) even showed a strong increase in loco-
motor activity, which may originate from the anxiolytic effect of
DZP occurring through a2GABAARs (ref. 12). Impairment of
muscle strength was assessed in the horizontal wire test.
Signiﬁcant muscle relaxation was detected in wt mice and in
mice with BDZ-sensitive GABAARs of either only the a2 (RHRR
mice) or a3 subtype (RRHR mice; Fig. 4b). Motor coordination,
tested in the rotarod test, was signiﬁcantly impaired by DZP in
mice with only a1 (HRRR mice) and with only a3 BDZ-sensitive
GABAARs (RRHR mice; Fig. 4c). Quadruple point-mutated
(RRRR) mice were completely protected from DZP-induced
muscle relaxation and motor impairment. They did, however,
show a trend towards reduced locomotor activity (compare
Fig. 4a). We therefore assessed changes in locomotion also after
higher DZP doses in the quadruple point-mutated mice and
found signiﬁcant and dose-dependent impairment starting at
30mg kg 1 (Fig. 4d). Unlike a1GABAAR-mediated sedation,
impairment of muscle strength was absent in the quadruple
point-mutated mice even at doses Z30mg kg 1. The sedative
action of DZP remaining in the quadruple point-mutated mice
may be attributed to a low-afﬁnity BDZ-binding site at
a1GABAARs described earlier21,22.
Our ﬁndings on the contribution of a1, a2 and a3GABAARs
to sedation, anxiolysis and muscle relaxation conﬁrm previous
studies using single GABAAR point-mutated mice11,12,23. The
results from our experiments with triple point-mutated mice on
motor coordination, however, differ from those obtained with
single point-mutated mice11,12. This discrepancy may arise from
the involvement of mixed GABAARs containing a1 and a3
subunits. We therefore tested whether motor coordination would
also be impaired by TP003, an a3GABAAR-selective BDZ site
agonist24. Two hours after treatment with TP003 (10mg kg 1,
p.o.), the time to fall off the rod was similarly decreased in wt and
RRHR mice (by 43.9±10.2%, paired t-test Po0.05, n¼ 5, in wt
mice, and by 38.5±6.4, n¼ 5, Po0.05), while HHRH and
vehicle-treated wt mice showed no impairment (0.7±12.0%,
n¼ 5, P¼ 0.91 and  4.7±9.2%, n¼ 5, P¼ 0.59).
Liability to tolerance development. Another major limitation of
classical BDZs is their liability to tolerance development (that is,
the loss of activity during prolonged use). We tested whether this
tolerance would also occur for the antihyperalgesic actions of
BDZs and whether it could be prevented by selectively targeting
a2GABAARs. To this end, we applied again CCI surgery and
treated mice of the different strains for nine consecutive days with
10mg kg 1 DZP or vehicle p.o. once daily. On the 10th day, both
groups of mice were split into two subgroups, treated with either
10mg kg 1 DZP or vehicle, and mechanical hypersensitivity was
monitored for 2 h after drug application. We ﬁrst did this
experiment in single a1 point-mutated (RHHH) mice to avoid
confounding sedation (Fig. 5a,d). While DZP-naive mice
responded with an almost complete reversal of hyperalgesia, mice
chronically pretreated with DZP showed no antihyperalgesic
response. We then performed this experiment in triple point-
mutated RHRR mice with only a2 BDZ-sensitive GABAARs
and found that these mice were completely protected from
tolerance development (Fig. 5b,d). In the latter experiment,
the antihyperalgesic response was generally lower than in a1
point-mutated (RHHH) mice. We therefore repeated the ﬁrst
experiment with a lower dose of DZP (3mg kg 1) to exclude the
possibility that the absence of tolerance in the RHRR mice was
Table 1 | Baseline nociceptive sensitivities of all GABAAR genotypes under study.
Genotype BDZ-sensitive a subunit (-s) Pre-CCI Post-CCI
von Frey (g)
(number of mice)
Hargreaves (s)
(number of mice)
von Frey (g)
(number of mice)
Hargreaves (s)
(number of mice)
HHHH (wt) a1, a2, a3 and a5 4.04±0.07 (20) 22.9±0.72 (17) 1.48±0.23 (8) 11.7±1.03 (16)
RHHH a2, a3 and a5 4.41±0.11 (23) 22.6±0.63 (15) 1.52±0.11 (15) 9.68±0.81 (12)
RHHR a2 and a3 4.21±0.12 (26) 23.4±0.57 (15) 1.46±0.09 (20) 10.4±1.15 (10)
RHRH a2 and a5 4.05±0.09 (23) 22.9±0.60 (20) 1.26±0.10 (9) 12.8±1.70 (7)
RRHH a3 and a5 4.23±0.04 (29) 21.0±0.43 (29) 1.52±0.06 (8) 8.54±0.62 (19)
RHRR a2 4.12±0.06 (32) 22.2±0.53 (32) 1.42±0.11 (18) 10.7±0.72 (19)
RRHR a3 4.12±0.12 (29) 22.2±0.50 (29) 1.27±0.08 (13) 10.3±1.00 (9)
RRRH a5 4.32±0.07 (23) 21.5±0.42 (23) 1.67±0.08 (11) 10.2±0.89 (12)
RRRR None 3.99±0.10 (9) 20.8±1.48 (6) 1.18±0.16 (9) 10.3±1.51 (6)
Statistics F(8,205)¼ 1.57; PZ0.06 F(8,177)¼ 1.93; PZ0.06 F(8,102)¼ 1.78; PZ0.16 F(8,101)¼ 1.80; PZ0.09
ANOVA, analysis of variance; BDZ, benzodiazepine; CCI, chronic constriction injury; GABAAR, GABAA receptor.
Values are given as mean±s.e.m.
ANOVA followed by Dunnett’s post hoc test with wt (HHHH) as control.
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due to a smaller DZP effect. With this lower dose, complete
tolerance still developed in RHHH mice (Fig. 5c,d). These
experiments indicate that activity at a3 or a5GABAARs was
necessary to induce antihyperalgesic tolerance. We therefore
tested double point-mutated mice in which a3GABAARs or
a5GABAARs were left BDZ-sensitive in addition to a2GABAARs
(RHHR and RHRH mice). Complete tolerance developed in
RHHR mice, but not in RHRH mice, indicating that activity at
a3GABAARs was necessary for induction of antihyperalgesic
tolerance in mutated mice (Fig. 5e). In this set of experiments, we
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Figure 2 | Antihyperalgesia by per oral DZP in GABAAR point-mutated mice. (a) Reversal of mechanical hyperalgesia by DZP in a1 point-mutated
(RHHH) mice assessed with von Frey ﬁlaments 7 days after CCI surgery. (b) Dose–response relationship. Data were ﬁtted to Hill’s equation. ***Po0.001;
**Po0.01 versus vehicle (ANOVA F(4,28)¼ 29.0 followed by Dunnett’s post hoc test, n¼ 7, 7, 6, 7 and 6 mice, for vehicle and 1, 10 and 30mg kg 1 DZP,
respectively). (c,d) Reversal of mechanical (c) and heat hyperalgesia (d) by DZP (10mg kg 1) 1 week after the CCI surgery. All mice except wt carried the
H-R point mutation in a1GABAARs to avoid sedation. (e) Comparison of antihyperalgesia (determined from 70 to 130min after DZP administration) in
GABAAR triple point-mutated mice. ***Po0.001; **Po0.01; versus vehicle-treated wt mice (ANOVA followed by Dunnett’s post hoc test, F(4,54)¼ 36.2
and F(4,53)¼ 15.1 for von Frey and Hargreaves tests, respectively). No antihyperalgesia by DZP occurred in quadruple GABAAR point-mutated mice
(P¼0.85 and 0.94). (f) Comparison of antihyperalgesia by DZP in RHRR mice with that of mice carrying, in addition, BDZ-sensitive a3 and/or
a5GABAARs. No signiﬁcant differences were observed (ANOVA followed by Dunnett’s post hoc test, von Frey: F(3,57)¼ 2.96; PZ0.12. Hargreaves:
F(3,44)¼0.98; PZ0.37). (g) Antihyperalgesia in triple GABAAR point-mutated mice with only one DZP-sensitive GABAAR subtype (grey columns)
compared with antihyperalgesia lost through H-R point mutation of the same subunit (light red columns). Antihyperalgesia in triple point-mutated mice is
expressed as percentage of antihyperalgesia in RHHH mice. Loss of antihyperalgesia was calculated as the reduction in antihyperalgesia relative to
RHHH mice. ***Po0.001; **Po0.01; *Po0.05 (unpaired t-tests). Number of mice in c–g: vehicle-treated wt (von Frey/Hargreaves test) n¼ 7/11, RHHH
n¼ 15/12, RHRR n¼ 18/19, RRHR n¼ 13/9, RRRH n¼ 11/12, RHHR n¼ 19/10, RHRH n¼ 9/7, RRRR n¼ 9/6, RRHH n¼ 8/19. (h) Formalin test. Reduction
by DZP (10mg kg 1) in the number of ﬂinches and licking bouts compared with vehicle-treated mice. ***Po0.001; **Po0.01; *Po0.05 (ANOVA followed
by Dunnett’s post hoc test. Flinches, F(3,24)¼ 6.71; licking bouts, F(4,25)¼ 10.7. n¼9, 6, 7 and 6 mice, for vehicle-treated wt and DZP-treated RHRR,
RRHR and RRRH mice, respectively. All data points are mean±s.e.m.
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ﬁnally tested whether the same subtype dependence would also be
found for tolerance against a2GABAAR-mediated anxiolysis
(Fig. 5f). Unlike antihyperalgesic tolerance, anxiolytic tolerance
(measured as increased locomotor activity in the open ﬁeld) still
developed in RHRR mice. This dissociation suggests that toler-
ance development against antihyperalgesia is not a receptor or
cell-autonomous process25 but rather occurs at the circuit level.
Why classical BDZs lack clinically relevant analgesic proper-
ties. Our present results and previous pain studies employing
subtype-selective BDZ site agonists in rodents5,20,26–29 contrast
with the lack of a clear analgesic or antihyperalgesic action of
classical BDZs in human patients30,31. Apart from species
differences and differences between disease models and actual
disease in human patients, we found one possible explanation
particularly worth studying. The doses and the degrees of
receptor activation required for a relevant effect might be
signiﬁcantly higher in case of antihyperalgesia than of sedation.
As a consequence, antihyperalgesia would occur in patients only
at doses already inducing strong sedation. The availability of the
triple point-mutated mice allowed us to directly compare the
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Figure 3 | Antihyperalgesia by the non-sedative BDZ HZ-166 occurs
through a2GABAARs. (a) HZ-166 (16mg kg 1, i.p.,) almost completely
reversed CCI-induced mechanical sensitization in wt mice (HHHH, black),
but not in a2 (H101R) mice (HRHH mice, red). (b) Statistical analysis.
**Po0.01 (unpaired t-test), n¼ 7 and 8 mice, for wt and a2 (H101R) mice.
All data points are mean±s.e.m.
Table 2 | Baseline locomotor activity and performance in the horizontal wire and rotarod tests.
Genotype BDZ-sensitive
a subunit (-s)
Activity counts
(number of mice)
Horizontal wire performance*
(number of mice)
Rotarod performancew
(number of mice)
HHHH (wt) a1, a2, a3 and a5 962±114 (14) 92±2.5 (17) 92±5.6 (5)
HRRR a1 1102±104 (9) 98±1.2 (9) 98±8.2 (6)
RHRR a2 1132±106 (8) 96±1.2 (8) 81±5.3 (5)
RRHR a3 1279±114 (10) 99±1.1 (10) 85±7.7 (5)
RRRH a5 987±90.4 (8) 100±0.0 (8) 84±11 (5)
RRRR None 1037±115 (9) 99±1.2 (9) 110±13 (5)
Statisticsz F(5,52)¼ 1.16; PZ0.13 F(5,55)¼ 2.10; PZ0.70 F(5,25)¼ 1.53; PZ0.47
ANOVA, analysis of variance; BDZ, benzodiazepine; wt, wild type.
Values are given as mean±s.e.m.
*Horizontal wire performance, expressed as success rate (%).
wRotarod performance, expressed as time before fall off (s).
zANOVA followed by Dunnett’s post hoc test with wt (HHHH) as control.
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doses and levels of receptor occupancy at the relevant GABAAR
subtypes and sites. For these experiments, we chose midazolam
(MDZ) as a second classical BDZ in addition to DZP. First, we
determined for both drugs their a2/a1 selectivity proﬁles in
electrophysiological experiments on recombinant GABAARs. As
expected, we found that DZP potentiated a1/b2/g2 and a2/b3/g2
GABAARs with similar efﬁcacy and potency (Fig. 6a and Table 3).
By contrast, MDZ potentiated a1/b2/g2 GABAARs more than
twice as much as a2/b3/g2 GABAARs (Fig. 6b and Table 3). We
then veriﬁed that the H-R point mutation blocked not only
DZP effects but also MDZ binding and GABAAR potentiation
(Figs 6c,d; see also ref. 32). Next, we compared the dose
dependency of DZP- and MDZ-induced antihyperalgesia in mice
with only a2 BDZ-sensitive GABAARs (RHRR mice) with that of
DZP- and MDZ-induced sedation in mice with only a1 BDZ-
sensitive GABAARs (HRRR mice). We found that half maximal
sedation occurred already at a doses of 0.33±0.05 and
0.52±0.11mg kg 1 (mean±s.d.) for DZP and MDZ,
respectively, while half maximal antihyperalgesia required
8±6mg kg 1 (DZP) and 10.4±2.0mg kg 1 (MDZ). A
rightward shift of the response curve was also observed when
the degrees of receptor occupancy required for antihyperalgesia
and for sedation were compared. Half maximal sedation was
reached when DZP had bound 47±6% brain a1GABAARs,
while half maximal antihyperalgesia required 71±2%
occupancy at spinal a2GABAARs. In case of MDZ, the required
receptor occupancies were even further apart (24±2%
of brain a1GABAARs and 71±2% of spinal a2GABAARs)
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consistent with the even less favourable a2/a1 selectivity ratio of
MDZ. These data indicate that, when applied to wt mice, the DZP
and MDZ doses needed for half maximal antihyperalgesia induce
an almost complete (B95%) reduction in locomotor activity,
while at non-sedative doses both BDZs would not induce
signiﬁcant antihyperalgesia. Dose-limiting sedation is therefore
the most likely reason for the absence of a relevant
antihyperalgesic activity of classical, nonselective BDZs in
human patients.
Discussion
In the present study we have employed triple GABAAR
point-mutated mice to characterize the pharmacological
actions expected from yet-to-be-developed subtype-selective
BDZ-binding site agonists. Our study can be viewed as a
‘restriction-of-function’ approach (‘what effect of DZP
remains when only a single GABAAR subtype is targeted?’)
as opposed to previous loss-of-function studies in single
GABAAR point-mutated mice (‘which effects of DZP are
lost or reduced when activity at one GABAAR subtype is
abolished compared with DZP-treated wt mice?’). With
respect to sedation, anxiolysis and the muscle-relaxant
action, the present study conﬁrms previous results obtained with
single point-mutated mice: sedative actions of BDZs occur
through a1GABAAR (refs 10,11), anxiolytic effects through
a2GABAARs (ref. 12) and muscle relaxation through a2 and
a3GABAAR (ref. 23).
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surgery. (e,f) Dose–response relationships. Data were ﬁtted to Hill’s equation with baseline ﬁxed at 0. Sedation and antihyperalgesia were determined
between 15 and 90min after oral DZP (e) or between 15 and 60min after oral MDZ (f). Mice were killed immediately afterwards (that is, at the time point
of maximal effects), and brains and spinal cords were removed for further analyses. (g,h) Dependence on receptor occupancy (RO). (g) Sedation versus RO
in brains of HRRR mice treated with DZP (0.03, 0.1, 0.3, 1, 3, 10 and 30mg kg 1, n¼6 mice for all doses). Antihyperalgesia versus RO in lumbar spinal
cords of RHRR mice treated with 0.1, 1, 3, 10 or 30mg kg 1 DZP, n¼ 6 mice for all doses. (h) Same as g but MDZ. Sedation 0.1 (n¼ 6 mice), 0.3 (7), 0.5
(7), 1.0 (7), 3 (6) and 10 (4) mg kg 1. Antihyperalgesia 0.1 (n¼ 3), 0.3 (5), 1.0 (9), 3 (8), 5 (7) and 10 (7) mg kg 1 MDZ. Data were ﬁtted to sigmoidal
functions. Data shown in e,g (on DZP) and in f,h (on MDZ) are from the same two groups of mice. All data points are mean±s.e.m.
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Discrepancies between results from restriction-of-function and
loss-of-function approaches were observed for impairment of
motor coordination. The present study shows that undesired
impairment of motor coordination is caused by DZP in HRRR
and RRHR mice (that is, it is evoked when either a1 or
a3GABAARs are speciﬁcally targeted), while previous reports in
the respective single point-mutated mice failed to provide
evidence for an involvement of these GABAAR subtypes11,12.
This discrepancy is consistent with the idea that DZP impairs
motor coordination through mixed GABAARs containing an a1
and an a3 subunit (a1/a3GABAARs). Immunohistochemical
analyses have shown that co-expression of a1 and a3 GABAAR
subunits occurs in subsets of central neurons33,34, and
biochemical data have provided direct evidence for the presence
of different a subunits within the same GABAAR complex15. In
particular, a3 containing GABAARs occur mainly as mixed
a1/a3GABAARs (refs 14,15). Furthermore, biochemical data
also suggest that in mixed GABAARs with one point-mutated a
subunit the nonpoint-mutated (wt) subunit has a higher
probability for interaction with the g2 subunit than the
point-mutated a subunit15,16. Results from loss-of-function
analysis in single point-mutated mice and from restriction-of-
function analyses in triple point-mutated mice should therefore
be seen as lower and upper limits for the contribution of a
given GABAAR subtype to an in vivo drug action. Conversely, the
lack of sedation in a1 point-mutated mice10,11 and of anxiolysis
in a2 point-mutated mice12 suggests that these actions
occur through GABAARs with only a single type of a subunit.
In line with this conclusion is that the majority of GABAARs in
the brain are pure a1GABAARs (a1/a1GABAARs)15. Similarly,
BDZ-mediated anxiolysis occurs through pure a2GABAARs, with
a2/a2GABAARs being the single most prevalent isoform of a2
containing GABAARs at supraspinal sites15.
As demonstrated by our autoradiography experiments (com-
pare Fig. 1d,e), mixed GABAARs make up the vast majority of
GABAARs in the spinal cord. Following the model described
above, one would expect that in case of mixed GABAARs the
single point mutation approach would yield smaller effects than
the triple point mutation strategy. For instance, in case of an ax/
ayGABAAR neither the ax single point mutation nor the ay
single point mutation would abolish BDZ sensitivity; however,
both triple point-mutated mice with only ax or only ay
remaining BDZ-sensitive would yield full behavioural effects.
Results for antihyperalgesia obtained in the present study were
consistent with a contribution of mixed GABAARs to antihyper-
algesia. For all three contributing a subunits, the loss-of-function
obtained through point mutation of one a subunit was smaller
than the restriction-of-function in the respective triple point-
mutated mouse. The discrepancies were particularly large for a3
in mechanical sensitization and for a5 in heat hyperalgesia,
suggesting that these effects occur mainly through mixed
GABAARs. Importantly, the rank orders of antihyperalgesic
efﬁcacy were the same for the restriction-of-function and loss-of-
function approaches with a24a54a3 for mechanical sensitiza-
tion and a24a34a5 for heat hyperalgesia and chemical
nociception. The same rank order of efﬁcacies has also been
reported previously for antihyperalgesia using local spinal
injections in single GABAAR point-mutated mice5. Our present
results therefore corroborate the critical importance of
a2GABAARs as targets for antihyperalgesia.
Our experiments on the quadruple point-mutated mice
indicate that antihyperalgesia, anxiolysis, muscle relaxation and
impairment of motor coordination occur through the high-
afﬁnity BDZ-binding site formed by the a/g interface. Among the
DZP actions assessed here, only sedation by high doses of DZP
occurred in quadruple point-mutated mice. This result is
consistent with previous electrophysiological data, which sug-
gested the presence of a low-afﬁnity BDZ-binding site in
a1GABAARs contributing to the anaesthetic actions of BDZs22.
Most BDZ effects quickly diminish during prolonged treatment
(that is, they undergo fast tolerance development). In the present
study, we show that this is also the case for antihyperalgesia.
Previous studies with the non-sedative BDZ site ligands
L-838,417 and HZ-166 showed that these compounds have
strongly reduced liabilities to tolerance development5,20,27. It has,
however, not been possible to attribute this reduced tolerance to
generally reduced agonistic activity or to improved subtype
speciﬁcity. Our present study shows that tolerance can be avoided
when only a2GABAARs are targeted, even with compounds that
exert full agonistic activity. Additional experiments in RHRH and
RHHR mice exclude a5GABAARs and suggest that activity at
a3GABAARs is required for tolerance induction. However,
because all these experiments were carried out in mice carrying
the H-R point mutation in the a1 subunit, we cannot exclude
Table 3 | PK/PD parameters* of DZP and MDZ.
DZP MDZ
a1/b2/c2 a2/b3/c2 a1/b2/c2 a2/b3/c2
EC50 (mM) 0.081±0.02 0.15±0.04 0.17±0.18 0.092±0.019
Emax (% pot IGABA) 91.6±7.7 103±11 235±43 75.8±4.7
nH 1.50±0.60 1.20±0.35 0.73±0.26 1.23±0.29
a2/a1 selectivityw 1.25 0.32
Sedation Analgesia Sedation Analgesia
ED50 (mg kg
 1) 0.33±0.05 7.6±0.6 0.52±0.11 10.4±2.0
Emax (%MPE) 93.6±4.5 100 (Fixed) 92.2±10.4 100 (Fixed)
nH 2.0±0.64 0.75±0.19 2.28±0.98 1.42±0.40
ED50 (sedation/analgesia) 0.043 0.050
Sedation Analgesia Sedation Analgesia
RO50 (%) 46.9±5.5 70.9±1.7 23.7±2.2 76.5±1.8
Emax 97.9±7.1 100 (Fixed) 94.7±11.8 100 (Fixed)
Rate 14.1±4.1 14.9±2.0 4.14±2.10 5.01±2.11
RO50 (sedation/analgesia) 0.66 0.31
PK, pharmacokinetic; PD, pharmacodynamic; DZP, diazepam; MDZ, midazolam; %MPE, percent maximal possible effect; RO, receptor occupancy.
For number of mice per group see Fig. 6.
*Values are mean±s.d.
wEmax (a2/b3/g2)/Emax (a1/b2/g2).
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that tolerance occurs through mixed a1/a3GABAARs, which in
the wt situation may exhibit an a1 pharmacology. Such a scenario
would explain why compounds with activity at a3GABAARs but
absent or reduced activity at a1GABAARs lack liability to
tolerance5,20,27. Interestingly, tolerance against the anxiolytic
action of DZP was retained in triple point-mutated RHRR mice
with only a2GABAARs remaining BDZ-sensitive. This difference
suggests that tolerance development against the different BDZ
effects involves activity at distinct subunits and possibly different
mechanisms. Cell- or receptor-autonomous processes, which
have been proposed for the desensitization of hippocampal
a2GABAARs (ref. 25), are unlikely to be responsible for the
tolerance against antihyperalgesia.
Addictive (reinforcing) properties of classical BDZs are another
area of concern that has not been addressed in the present study.
Reduced BDZ-induced reward facilitation has been reported in
mice carrying the H-R point mutation in either the a1, a2 or
a3GABAAR subunits35,36. Preference for MDZ in a two-bottle
choice paradigm was absent in a1 (refs 31,35) and a2 point-
mutated mice35, suggesting that the simultaneous positive
modulations of both the a1 and a2GABAAR are required for
reinforcement. Tan et al.32 reported that a1GABAARs on
GABAergic neurons in the ventral tegmental area (VTA) are
required for MDZ-induced neuronal plasticity, strengthening
glutamatergic excitation in the VTA. These ﬁndings suggest that
activity at more than one GABAAR subtype is necessary for BDZ
reinforcement. a2-selective BDZ site agonists might therefore be
largely devoid of addictive properties.
Previous studies have provided evidence that activation of
supraspinal GABAARs might enhance pain and counteract spinal
antihyperalgesia, for example, through the inhibition of descending
antinociceptive ﬁbre tracts37–39. In our study, we did not observe
any pronociceptive actions of systemically administered DZP. If
such pronociceptive actions were relevant in the pain models used
here, they would occur through a1GABAARs whose functions in
nociception were not addressed in the present study. Any such
effects would be avoided by a1-sparing BDZ site agonists.
The availability of the triple GABAAR point-mutated mice
permitted a direct pharmacokinetic/pharmacodynamic compar-
ison of a1-mediated sedation and a2-mediated antihyperalgesia
in the absence of confounding behavioural effects from other
GABAAR subtypes. In case of DZP, ED50 values for sedation and
antihyperalgesia differed by a factor of more than 20, and a 50%
higher degree of receptor occupancy was needed for a2-mediated
antihyperalgesia compared with a1-mediated sedation. New
subtype-selective agents will therefore have to have a high degree
of a2 over a1 selectivity in order to achieve clinically relevant
antihyperalgesia in the absence of sedation. These data also
indicate that dose-limiting sedation most likely underlies the lack
of clinically relevant antihyperalgesic effects of presently used
(nonselective) BDZs. This is consistent with a recent clinical
study in human volunteers showing weak antihyperalgesic effects
at doses that caused only mild sedation40.
Which GABAAR subtype should be targeted for an optimal
beneﬁt-risk ratio in pain treatment? Both the present restriction-
of-function and loss-of-function experiments on systemic BDZ
administration and previous experiments with local spinal
injections and single GABAAR point-mutated mice5 attribute
the highest antihyperalgesic efﬁcacy to a2GABAARs. The present
study has shown that adding activity at a3GABAARs or
a5GABAARs increases antihyperalgesic efﬁcacy only moderately
or not at all. Because it is at present not known how the different
mixed GABAARs respond to subtype-selective agents, a
conservative prediction should be made on the basis of the
results obtained from triple point-mutated mice. These
experiments indicate that sedation is exclusively due to
activation a1GABAARs, which is also consistent with studies
using the subtype-selective agonist TPA023B that completely
lacks agonistic activity at a1GABAARs as well as sedation in
humans41. The present experiments also showed that impaired
motor coordination involves a1GABARs and/or a3GABAARs.
None of the undesired effects investigated in the present study
could be attributed to a5GABAARs. However, cognitive
impairment by nonselective BDZ likely originates from activity
at a5GABAARs, as a5GABAAR-selective inverse agonists enhance
cognitive capabilities42. Subtype-selective BDZ agonists targeting
only a2GABAARs should therefore have the best beneﬁt-risk
ratio. They will produce pronounced antihyperalgesia in the
absence of sedation and will not interfere with motor
coordination and should not lose antihyperalgesic activity
during prolonged treatment. They will however have anxiolytic
properties (at least during the beginning of the treatment) and
muscle-relaxant effects. Both of these actions may be beneﬁcial in
chronic pain patients. Because the side effects studied here are
relevant for other indications, we expect that our present ﬁndings
will beneﬁt not only the development of innovative subtype-
selective BDZs as analgesics but also as drugs for the treatment of
several prevalent psychiatric diseases43.
Methods
Mice. Experiments were performed in wt mice, and in homozygous single, double,
triple and quadruple (H-R) GABAAR point-mutated mice, that is, in mice
expressing different combinations of BDZ-sensitive and BDZ-insensitive GABAAR
a subunits. All mice were of the same genetic background (129X1/SvJ). Double,
triple and quadruple point-mutated mice were generated by cross-breeding single
point-mutated mice described earlier11,12,44.
Autoradiography. The distribution of BDZ-sensitive GABAAR subtypes in the
lumbar spinal cord was examined in 16-mm-thick horizontal sections, which were
cut from fresh-frozen spinal cords. Sections were incubated with 5 nM [3H]ﬂu-
mazenil (50 Cimmol 1) or 9 nM [3H]Ro15-4513 (22.7 Cimmol 1) diluted in
50mM Tris pH 7.4 for 120min on ice. After washing three times for 20 s in ice-
cold buffer, sections were dried and exposed along with [3H]-standards to a tri-
tium-sensitive phosphoimaging screen (Cyclone Storage Phosphor Screen, Perkin
Elmer). Quantiﬁcation was carried out using the Optiquant software (Perkin
Elmer). Nonspeciﬁc binding was assessed by co-incubating 10 mM clonazepam
([3H]ﬂumazenil binding) or 10 mM ﬂumazenil ([3H]Ro15–4513-binding).
Immunohistochemistry. The localization of GABAAR subunits was visualized on
40-mm-thick lumbar spinal cord cryosections by DAB immunoperoxidase staining
on sections from artiﬁcial cerebrospinal ﬂuid (aCSF)-perfused mice postﬁxed for
90min in 4% paraformaldehyde (PFA) (without picric acid)45. Antibodies were
home-made subunit-speciﬁc antisera45. Final dilutions were 1:20,000 (a1), 1:1,000
(a2), 1:10,000 (a3), 1:3,000 (a5) and 1:10,000 (g2). Images were taken with a bright
ﬁeld light microscope connected to a digital camera and processed with the
AxioVision Rel. 4.5 software where an intensity-gradient false-colour ﬁlter was
applied.
Behavioural experiments. All behavioural experiments were performed in 7- to
12-week-old female and male mice. Care was taken to ensure equal numbers of
female and male mice. All behavioural experiments were made by a male experi-
menter, blinded either to the genotype of the mice or to their treatment with drug
or vehicle. Permission for animal experiments was obtained from the Veterina¨ramt
des Kantons Zu¨rich (licence numbers 135/2009 and 126/2012).
DZP (suspended in 0.9% saline and 1% Tween80) and MDZ (dissolved in 0.9%
saline pH 3.0) were applied orally in all experiments. HZ-166 (suspended in 0.5%
methyl cellulose) was given intraperitoneally (i.p.).
Neuropathic pain was evoked through CCI17 of the left sciatic nerve proximal
to the trifurcation with three loose (5-0 silk) ligatures. Mice, which showed signs of
paralysis or which did not develop signiﬁcant hypersensitivity, were excluded from
subsequent experiments. Effects of DZP and MDZ (p.o. in 0.9% saline and 1%
Tween 80) on thermal and mechanical hyperalgesia were assessed 1 week after
surgery. Heat hyperalgesia was quantiﬁed as the change in the latency of paw
withdrawal evoked by exposure of the plantar side of one hindpaw to a deﬁned
radiant heat stimulus. Mechanical hyperalgesia was assessed with electronic von
Frey ﬁlament no. 7 (IITC, Woodland Hills, CA). Three to four measurements were
made for each time point and animal for both heat and mechanical hyperalgesia.
Percent maximal possible effect (%MPE) was calculated as follows:
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%MPE(t)¼ (E(t)Epredrug))/(EpreCCIEpredrug); E(t), paw withdrawal
thresholds or latency at time point t. Epredrug, E after CCI surgery but before DZP
application; EpreCCI, E baseline before CCI surgery.
Formalin (4%, 20 ml) was injected subcutaneously into the plantar surface of the
left hindpaw. Flinches and licks of the injected paw were counted for 1 h in 5-min
intervals starting immediately after formalin injection. DZP was administered p.o.
60min before formalin.
Locomotor activity was measured in an open ﬁeld arena (10 cm diameter)
equipped with four pairs of light beams and photosensors. Mice were placed into
the arena 75min before DZP application. Locomotor activity was analysed for the
time interval between 20 and 165min after DZP administration.
Motor control was assessed with a rotarod accelerating from 4 to 40 r.p.m.
within 5min. Sixty minutes after DZP administration mice were placed on the
rotarod. Five measurements were taken per mouse.
To assess muscle relaxation, mice were placed with their forepaws on a metal
horizontal wire placed 20 cm above ground. Successes and failures to grab the wire
with at least one hindpaw were recorded between 60 and 180min after DZP
administration.
Electrophysiology. The effects of DZP and MDZ on currents through recombi-
nant GABAARs were studied in HEK293 cells (ATCC) transiently expressing
GABAARs. HEK293 cells were transfected using lipofectamine LTX46. To ensure
expression of the g2 subunit (required for modulation of GABAARs by BDZs) in all
recorded cells, we transfected cells with a plasmid expressing the g2 subunit plus
enhanced green ﬂuorescent protein from an internal ribosomal entry site (IRES),
and only selected eGFP-positive cells for recordings. The transfection mixture
contained (in mg): 1 a1, 1 b2 and 3 g2/eGFP (used as a marker of successful
transfection) or 1 a2, 1 b3 and 3 g2/eGFP. Recordings were made at 18–36 h after
transfection. Whole-cell patch-clamp recordings of GABA-evoked currents were
made at room temperature (20–24 C) and at a holding potential of  60mV.
Recording electrodes were ﬁlled with solution containing (in mM): 120 CsCl, 10
EGTA, 10 HEPES (pH 7.40), 4 MgCl2, 0.5 GTP and 2 ATP. The external solution
contained (in mM): 150 NaCl, 10 KCl, 2.0 CaCl2, 1.0 MgCl2, 10 HEPES (pH 7.4)
and 10 glucose. GABA was applied to the recorded cell using a manually controlled
pulse (4–6 s) of a low subsaturating GABA concentration (EC5). EC5 values of
GABA were determined for wt a1b2g2, wt a2b3g2 and mutant a1(H101R)b2g2
receptors. EC50 values and Hill coefﬁcients (nH) were obtained from ﬁts of
normalized concentration–response curves to the equation IGABA¼ Imax
[GABA]nH/([GABA]nHþ [EC50]nH). Imax was determined as the average maximal
current elicited by a concentration of 1mM GABA. DZP and MDZ dissolved in
DMSO and subsequently diluted with recording solution were co-applied together
with GABA without preincubation.
[3H]Ro 15-4513-binding assay to recombinant GABAARs. HEK293 cells were
maintained in DMEM supplemented with 10% fetal bovine serum and seeded to a
density of 500,000 cells on poly-lysine-coated 100-mm culture dishes 1 day before
transfection. Cells were transfected with plasmids containing the subunit combina-
tion a1b2g2 or a1(H101R)b2g2 (7mg total DNA, ratio 1:1:2) using jetPEI trans-
fection reagent (Polyplus transfection). Twenty-four hours after transfection,
HEK293 cells were harvested in PBS. HEK293 cells were homogenized in 10mM Tris
pH 7.5, protease inhibitor cocktail (complete Mini, Roche Applied Science). Aliquots
of the homogenate prepared from HEK293 cells expressing the a1b2g2 or
a1(H101R)b2g2 subunit combination were incubated with increasing concentrations
of MDZ and 6.3 nM [3H]Ro15-4513 (22.7Cimmol 1, PerkinElmer) in a total
volume of 200ml for 90min on ice. Subsequently, the samples were ﬁltered on glass
ﬁbre ﬁlters using a 12-channnel semiautomated cell harvester (Scatron) and washed
with ice-cold buffer (10mM Tris-HCl pH 7.4). Nonspeciﬁc [3H]Ro15-4513 binding
was measured using 10mM ﬂumazenil. The radioactivity of the ﬁlters was determined
by liquid scintillation counting using a Tricarb 2500 liquid scintillation analyser.
Receptor occupancy. Mice were killed immediately after completion of the
behavioural tests, that is, 90min after DZP administration and 60min after MDZ
administration. Brains and spinal cords were removed and kept frozen until further
processing. Percentage of receptors occupied by DZP or MDZ was determined
ex vivo with [3H]ﬂumazenil as radioligand47. Frozen brains or lumbar spinal cords
were rapidly homogenized in 20 volumes 10mM Tris pH 7.4, 100mM KCl and
100ml aliquots were immediately added to 400 ml ice-cold buffer containing 4 nM
[3H]ﬂumazenil. After 30 s of incubation, samples were ﬁltered on Whatman GF/C
glass ﬁbre ﬁlters and washed three times with 4ml ice-cold buffer. Radioactivity
retained on the ﬁlters was determined by scintillation counting. To determine
nonspeciﬁc [3H]ﬂumazenil binding, mice were used that had been injected i.p. with
5mg kg 1 bretazenil (dissolved in PEG300) to fully occupy all BDZ-binding sites
(100% receptor occupancy47).
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